IN8bio names COO Kate Rochlin as President

IN8bio, Inc. announced that its Board of Directors appointed Chief Operating Officer Kate Rochlin as President of the company, effective February 4, 2026.

Accepted by SEC EDGAR 02/09/2026 - 08:31 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IN8bio, Inc. announced that its Board of Directors appointed Chief Operating Officer Kate Rochlin as President of the company, effective February 4, 2026. She will hold both roles of President and Chief Operating Officer, providing continuity in executive leadership. The company notes that there are no family relationships or related-party transactions involving Dr. Rochlin that require disclosure under the SEC’s executive and related-party rules.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership change did IN8bio (INAB) report in this 8-K?

IN8bio appointed Chief Operating Officer Kate Rochlin as President effective February 4, 2026. She will continue serving as Chief Operating Officer while taking on the President role, indicating leadership continuity at the company without changing her existing operational responsibilities.

When did Kate Rochlin become President of IN8bio (INAB)?

Kate Rochlin became President of IN8bio effective February 4, 2026. The Board of Directors approved her appointment on that date, and she will simultaneously continue in her position as Chief Operating Officer following this leadership change.

Will Kate Rochlin remain Chief Operating Officer at IN8bio (INAB)?

Yes, Kate Rochlin will remain Chief Operating Officer while also serving as President. The Board’s decision means she holds both executive titles, combining responsibility for overall leadership and day-to-day operations within IN8bio’s senior management team.

Does IN8bio (INAB) disclose any family relationships involving Kate Rochlin?

IN8bio states there is no family relationship involving Kate Rochlin requiring disclosure. The company confirms that no family ties exist that would trigger reporting under Item 401(d) of Regulation S-K, which addresses certain relationships among key executives and directors.

Are there related-party transactions involving IN8bio’s President Kate Rochlin?

IN8bio reports that Kate Rochlin is not party to related-party transactions requiring disclosure. Specifically, the company notes there are no transactions involving her that fall under Item 404(a) of Regulation S-K, which covers certain relationships and dealings with related persons.

Where can investors find biographical information on IN8bio’s President Kate Rochlin?

Biographical information on Kate Rochlin is incorporated by reference from IN8bio’s 2025 Proxy Statement. The company directs readers to the “Executive Officers” section of the proxy filed on April 29, 2025, for details about her background and experience.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001740279 0001740279 2026-02-04 2026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2026

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39692		82-5462585
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

350 5th Avenue, Suite 5330
New York, New York		10118
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (646) 600-6438

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		INAB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 4, 2026, the Company’s Board of Directors appointed Kate Rochlin, the Company’s Chief Operating Officer, as President of the Company, effective February 4, 2026. Dr. Rochlin will continue to serve as the Company’s Chief Operating Officer.

Biographical information about Dr. Rochlin can be found in the section of the Company’s 2025 Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2025, entitled “Executive Officers,” which is incorporated by reference herein.

There is no family relationship between Dr. Rochlin and any other person that would require disclosure under Item 401(d) of Regulation S-K. Dr. Rochlin is also not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				IN8bio, Inc.
Date: February 9, 2026				By:		/s/ Patrick McCall
						Patrick McCall
						Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB